• +1-646-491-9876
    • +91-20-67278686

    Search

    Nocturia-Pipeline Review H2 2017

    Nocturia-Pipeline Review H2 2017

    • Report Code ID: RW0001881468
    • Category Life Sciences
    • No. of Pages 29
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Nocturia-Pipeline Review H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Nocturia-Pipeline Review H2 2017 provides an overview of the Nocturia (Genito Urinary System And Sex Hormones) pipeline landscape.

    Nocturia is defined as need to urinate at least twice during the night. This condition becomes more common as people age and occurs in both men and women sometimes for different reasons. Causes of nocturia include congestive heart failure edema of lower extremities sleeping disorders such as obstructive sleep apnea certain drugs including diuretics (water pills) cardiac glycosides demeclocycline lithium methoxyflurane phenytoin propoxyphene and excessive vitamin d and drinking too much fluid before bedtime especially coffee caffeinated beverages or alcohol. Treatment includes anticholinergic medications.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Nocturia-Pipeline Review H2 2017 provides comprehensive information on the therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones) complete with analysis by stage of development drug target mechanism of action (MoA) route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics its complete research and development history and latest news and press releases.

    The Nocturia (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Nocturia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes the molecules developed by Companies in Phase III Phase II and Phase I stages are 2 3 and 2 respectively.

    Nocturia (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases company/university websites clinical trial registries conferences SEC filings investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Nocturia (Genito Urinary System And Sex Hormones) .
    - The pipeline guide reviews pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise product description descriptive licensing and collaboration details R&D brief MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Nocturia (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Nocturia (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA) drug target route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Nocturia (Genito Urinary System And Sex Hormones)

    Reasons to buy

    - Procure strategically important competitor information analysis and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Nocturia (Genito Urinary System And Sex Hormones) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Nocturia (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Nocturia-Overview
    Nocturia-Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Nocturia-Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Nocturia-Companies Involved in Therapeutics Development
    Astellas Pharma Inc
    Ferring International Center SA
    Sanwa Kagaku Kenkyusho Co Ltd
    Vantia Therapeutics
    Nocturia-Drug Profiles
    (acetaminophen + ibuprofen)-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-7035-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ASP-7398-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    desmopressin acetate ODT-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FE-201836-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    fedovapagon-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SK-1404-Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Nocturia-Dormant Projects
    Nocturia-Product Development Milestones
    Featured News & Press Releases
    Feb 13 2017 Scottish Medicines Consortium Rejects Noqdirna For Use Within NHS Scotland
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Nocturia H2 2017
    Number of Products under Development by Companies H2 2017
    Products under Development by Companies H2 2017
    Number of Products by Stage and Target H2 2017
    Number of Products by Stage and Mechanism of Action H2 2017
    Number of Products by Stage and Route of Administration H2 2017
    Number of Products by Stage and Molecule Type H2 2017
    Nocturia-Pipeline by Astellas Pharma Inc H2 2017
    Nocturia-Pipeline by Ferring International Center SA H2 2017
    Nocturia-Pipeline by Sanwa Kagaku Kenkyusho Co Ltd H2 2017
    Nocturia-Pipeline by Vantia Therapeutics H2 2017
    Nocturia-Dormant Projects H2 2017

    List of Figures

    Number of Products under Development for Nocturia H2 2017
    Number of Products under Development by Companies H2 2017
    Number of Products by Targets H2 2017
    Number of Products by Stage and Targets H2 2017
    Number of Products by Mechanism of Actions H2 2017
    Number of Products by Stage and Mechanism of Actions H2 2017
    Number of Products by Routes of Administration H2 2017
    Number of Products by Stage and Routes of Administration H2 2017
    Number of Products by Molecule Types H2 2017
    Number of Products by Stage and Molecule Types H2 2017
    Astellas Pharma Inc
    Ferring International Center SA
    Sanwa Kagaku Kenkyusho Co Ltd
    Vantia Therapeutics

    Request for Sample

    Report Url http://www.reportsweb.com//nocturia-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//nocturia-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//nocturia-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments